Incyte (INCY)
(Delayed Data from NSDQ)
$59.16 USD
+0.75 (1.28%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $59.16 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Incyte Corporation [INCY]
Reports for Purchase
Showing records 61 - 80 ( 248 total )
Company: Incyte Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Incyte Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Incyte Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Incyte Corporation
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Incyte Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Incyte Corporation
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Incyte Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Incyte Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Incyte Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Incyte Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Incyte Corporation
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended May 8
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Incyte Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Incyte Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Incyte Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Incyte Corporation
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended April 10
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Incyte Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Incyte Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Incyte Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Incyte Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Incyte Corporation
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended February 14
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D